Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Current Deferred Revenue (2020 - 2024)

Historic Current Deferred Revenue for Molecular Partners Ag (MOLN) over the last 5 years, with Q2 2024 value amounting to $646889.2.

  • Molecular Partners Ag's Current Deferred Revenue fell 9003.69% to $646889.2 in Q2 2024 from the same period last year, while for Jun 2024 it was $646889.2, marking a year-over-year decrease of 9003.69%. This contributed to the annual value of $4.9 million for FY2023, which is 2657.36% down from last year.
  • Per Molecular Partners Ag's latest filing, its Current Deferred Revenue stood at $646889.2 for Q2 2024, which was down 9003.69% from $2183.7 recorded in Q1 2024.
  • Molecular Partners Ag's 5-year Current Deferred Revenue high stood at $30.7 million for Q4 2021, and its period low was $2183.7 during Q1 2024.
  • Moreover, its 5-year median value for Current Deferred Revenue was $2.8 million (2023), whereas its average is $5.5 million.
  • As far as peak fluctuations go, Molecular Partners Ag's Current Deferred Revenue surged by 29653.97% in 2021, and later plummeted by 9003.69% in 2024.
  • Over the past 5 years, Molecular Partners Ag's Current Deferred Revenue (Quarter) stood at $7.7 million in 2020, then surged by 296.54% to $30.7 million in 2021, then tumbled by 78.33% to $6.7 million in 2022, then dropped by 26.57% to $4.9 million in 2023, then plummeted by 86.76% to $646889.2 in 2024.
  • Its last three reported values are $646889.2 in Q2 2024, $2183.7 for Q1 2024, and $4.9 million during Q4 2023.